Optimizing CAR T-Cell Therapy in DLBCL With Community and Academic Perspectives - Episode 2

Bispecific Antibodies vs CAR T-Cell Therapy: Treatment Selection and Sequencing in Later-Line R/R DLBCL

March 27, 2025

Experts discuss how they sequence bispecifics and other available therapies in the third-line setting and beyond for patients who did not receive chimeric antigen receptor T-cell therapy (CAR T) in the second-line setting, and whether their approach changes for those who have or have not received prior auto-transplant.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Integrating CAR T-Cell Therapy Into the Treatment Landscape for R/R DLBCL

Now Viewing

EP. 2: Bispecific Antibodies vs CAR T-Cell Therapy: Treatment Selection and Sequencing in Later-Line R/R DLBCL

EP. 3: Selecting Candidates for CAR T-Cell Therapy in R/R DLBCL: Patient Characteristics, Eligibility, and Timing Considerations

EP. 4: Expert Insights for Approaching Patient Counseling for CAR T-Cell Therapy in R/R DLBCL

EP. 5: Practical Realities of CAR T-Cell Therapy for R/R DLBCL: Challenges and Lessons From the Community

EP. 6: Optimal Strategies for Navigating Referral and Bridging Therapy for CAR T-Cell Therapy in R/R DLBCL Patients

EP. 7: Safety Considerations for CAR T-Cell Therapy in R/R DLBCL

EP. 8: Outpatient CAR T-Cell Therapy for R/R DLBCL: Opportunities, Challenges, and Solutions

EP. 9: The Future of CAR T-Cell Therapy in R/R DLBCL: Closing Reflections and Key Takeaways

Video content above is prompted by the following:

How are you sequencing other available therapies like bispecifics in the third-line setting and beyond for those who didn't get CAR T in the second-line setting? Does your thought process change for those who received prior auto-transplant or not?